knowledge -WSS

knowledge

author：explore 2025-09-07 14:03:50 - browse：928

The term “excited delirium” has been used for years by law enforcement and other first responders, including health care workers, to describe people who exhibit behavior that is considered “out of control.” This diagnosis has been applied again and again, even posthumously, as a justification for extreme, and sometimes deadly, interventions by law enforcement. It came up most recently in the trials of two police officers accused of causing the death of Elijah McClain, a Colorado man; both officers were acquitted this week.

But excited delirium is not an evidence-based medical diagnosis. The American College of Emergency Physicians recently withdrew a 2009 white paper endorsing the concept, and California has banned it as a cause of death. Other states may follow suit.

On this week’s episode, we are joined by Utsha G. Khatri, an assistant professor of emergency medicine and population health and policy at the Icahn School of Medicine at Mount Sinai, and emergency physician Brooks Walsh, who was involved with the campaign to get ACEP to withdraw the 2009 white paper. Khatri and Walsh speak about why the “excited delirium” label is both unnecessary and dangerous.

“We recognize that some patients are confused. They’re not thinking clearly they might have risk for becoming violent either toward themselves or towards other staff,” Khatri said. “It is our job not just to keep them and everyone else safe, but also to most importantly find out what is causing them to act in this way.”

You can read Khatri’s First Opinion essay on the end of “excited delirium” here.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： AI can’t replace a physician’s gut feeling

knowledge

hotspot

WSS

In early work, researchers turn to CRISPR to treat Alzheimer's

Flagship Pioneering launches a new biotech in two countries

Pediatric cancer treatments threatened by a new FDA policy

FDA approves RSV monoclonal antibody for infants, toddlers

What don’t we know about an Alzheimer’s drug side effect?

Medicare to cover more brain scans for Alzheimer’s patients

focus

knowledge

focus

As demand for Covid shots wanes, Moderna seeks its next success

Key House panel plots a new health care package

Trump demands the U.S. pay no more for drugs than other countries … again

Flagship Pioneering launches a new biotech in two countries

Guidelines to prevent youth baseball injuries need more muscle

CDC director unscathed in first congressional testimony

In Memoriam: Notable people who died in 2023

How dance can help nurses traumatized by Covid

Dobbs anniversary: the lost opportunity of abortion as health care

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

knowledge

U.K. Biobank has 500,000 peoples' genome sequences available

Startup Neumora takes a novel depression drug to Phase 3

Sanders adds drug shortage policies to pandemic preparedness bill

Doctors find melanoma drugs effective against rare brain cancer

Takeda, Janssen join wearable maker to measure scratching

How dance can help nurses traumatized by Covid

knowledge

hotspot

focus

focus